A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2ep53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours

被引：0
|
作者：
Schoeffski, P. [1 ]
Lorusso, P. [2 ]
Yamamoto, N. [3 ]
Lugowska, I. [4 ]
Garcia, V. Moreno [5 ]
Lauer, U. [6 ,7 ]
Hu, C. [8 ]
Jayadeva, G. [9 ]
Lahmar, M. [10 ]
Gounder, M. [11 ]
机构：
[1] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven Canc Inst, Leuven, Belgium
[2] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA
[3] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[4] Maria Sklodowska Curie Natl Res Inst Oncol, Early Phase Clin Trials Unit, Warsaw, Poland
[5] Hosp Fdn Jimenez Diaz, START Madrid, Madrid, Spain
[6] Univ Hosp Tubingen, Dept Med Oncol&Pneumol, Tubingen, Germany
[7] Univ Hosp Tubingen, Tubingen Early Phase Clin Trials Unit, Tubingen, Germany
[8] Boehringer Ingelheim Pharmaceut Inc, Global Biostat&Data Sci, Ridgefield, CT USA
[9] Boehringer Ingelheim Pharmaceut Inc, TA Oncol Med, Ridgefield, CT USA
[10] Boehringer Ingelheim Int GmbH, TA Oncol Med, Ingelheim, Germany
[11] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1859
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
673P
引用
收藏
页码：S472 / S473
页数：2
相关论文
共 50 条
  • [41] Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
    Wu, Y.
    Jing, H.
    Zhang, J.
    Cao, X.
    Li, K.
    Liu, Y.
    Meng, M.
    Li, H.
    Kang, W.
    Li, J.
    Wang, Q.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1497 - S1497
  • [42] iMATRIXcobi: A Phase I/II, Dose-Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of Cobimetinib in Paediatric and Young Adult Patients with Refractory/Relapsed Tumours
    Trippett, T.
    Simko, S.
    Ye, C.
    Caron, H.
    Geoerger, B.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S210 - S210
  • [43] A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors.
    Adjei, A. A.
    Sosman, J. A.
    Dy, G. K.
    Ma, W.
    Fetterly, G. J.
    Skupien, D.
    Means, J. A.
    Savage, R.
    Chai, F.
    Puzanov, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours
    Takashi Seto
    Taito Esaki
    Fumihiko Hirai
    Shuji Arita
    Kaname Nosaki
    Akitaka Makiyama
    Takuro Kometani
    Chinatsu Fujimoto
    Motoharu Hamatake
    Hiroaki Takeoka
    Felix Agbo
    Xiaojin Shi
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 619 - 627
  • [45] Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours
    Seto, Takashi
    Esaki, Taito
    Hirai, Fumihiko
    Arita, Shuji
    Nosaki, Kaname
    Makiyama, Akitaka
    Kometani, Takuro
    Fujimoto, Chinatsu
    Hamatake, Motoharu
    Takeoka, Hiroaki
    Agbo, Felix
    Shi, Xiaojin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (03) : 619 - 627
  • [46] Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
    Hong, D. S.
    Bauer, T. M.
    Lee, J. J.
    Dowlati, A.
    Brose, M. S.
    Farago, A. F.
    Taylor, M.
    Shaw, A. T.
    Montez, S.
    Meric-Bernstam, F.
    Smith, S.
    Tuch, B. B.
    Ebata, K.
    Cruickshank, S.
    Cox, M. C.
    Burris, H. A., III
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2019, 30 (02) : 325 - 331
  • [47] A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium
    S Lheureux
    A M Oza
    S A Laurie
    R Halford
    D Jonker
    E Chen
    D Keller
    V Bourade
    L Wang
    L Doyle
    L L Siu
    R Goel
    British Journal of Cancer, 2015, 113 : 1534 - 1540
  • [48] A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium
    Lheureux, S.
    Oza, A. M.
    Laurie, S. A.
    Halford, R.
    Jonker, D.
    Chen, E.
    Keller, D.
    Bourade, V.
    Wang, L.
    Doyle, L.
    Siu, L. L.
    Goel, R.
    BRITISH JOURNAL OF CANCER, 2015, 113 (11) : 1534 - 1540
  • [49] Phase I, open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors.
    Tolcher, Anthony W.
    Victoria, Ivan
    Germann, Nathalie
    Luecke, Stephan
    Bailey, Mark
    Kordes, Maximilian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an antiPD-1 antibody, in patients with advanced solid tumours
    Girard, N.
    Hackanson, B.
    Wermke, M.
    Barlesi, F.
    Landsteiner, H. T.
    Jayadeva, G.
    Alt, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 659 - 659
12345